WALTHAM, Mass.–(BUSINESS WIRE)–Xilio Therapeutics, Inc. (Xilio) a biotechnology firm creating tumor-selective immuno-oncology therapies for sufferers with most cancers, as we speak introduced that Timothy D. Hunt has been appointed as the corporate’s chief tradition and company affairs officer. On this function, Mr. Hunt will function a member of the manager group and can oversee human assets, communications and different strategic initiatives.
“Tim is an skilled company-builder with an intensive background in rising and scaling clinical-stage organizations, and I’m delighted he’s becoming a member of Xilio,” mentioned René Russo, Pharm. D., president and chief govt officer of Xilio. “With one program within the clinic and a second clinical-stage program anticipated this yr, Tim’s management will likely be important as we proceed to construct out our group, advance our sturdy tradition and successfully handle communications to our key exterior stakeholders.”
“Leveraging its GPS platform, Xilio has developed a pipeline of immuno-oncology product candidates designed to supply deep and sturdy scientific responses which have the potential to supply important benefits over presently obtainable remedies,” mentioned Mr. Hunt. “The progress made in a brief period of time is spectacular, and I’m happy to hitch this pushed and revolutionary group as we work to advance our lead packages for sufferers with most cancers.”
Mr. Hunt brings greater than 20 years of biotechnology expertise to Xilio, most just lately serving as chief company affairs officer at Editas Drugs, Inc. (Editas) the place he oversaw the human assets, market improvement and early-stage business planning, coverage and authorities affairs, and company communications capabilities from 2016 to 2020. Previous to Editas, he was senior vice chairman of public affairs for Cubist Prescribed drugs, Inc. (Cubist), a biotechnology firm centered on the event and commercialization of infectious illness therapeutics, from 2011 till its acquisition by Merck Analysis Laboratories in 2015. Earlier than becoming a member of Cubist, Mr. Hunt was vice chairman of public affairs at Biogen Inc. He presently serves as a member of the Board of Administrators of the non-profit group Life Sciences Cares and as chair of the Ethics Committee of the American Society of Gene and Cell Remedy. Mr. Hunt obtained a B.A. in historical past and philosophy from Boston Faculty and a J.D. from the Columbus College of Regulation on the Catholic College of America.
About Xilio Therapeutics
Xilio Therapeutics is a privately-held biotechnology firm centered on harnessing the immune system to realize deep and sturdy scientific responses to enhance the lives of sufferers with most cancers. The corporate is utilizing its proprietary geographically exact options (GPS) platform to quickly engineer novel molecules, together with cytokines and different biologics which can be designed to optimize their therapeutic index. These molecules are designed to localize exercise inside the tumor microenvironment with out systemic impact, ensuing within the potential to realize enhanced anti-tumor exercise. Xilio is constructing a pipeline of wholly owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, together with XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody; XTX202, a tumor-selective IL-2; XTX301, a tumor-selective IL-12; and XTX401, a tumor-selective IL-15. For extra info, please go to www.xiliotx.com.